$ALKS

Alkermes plc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$28.02 β–Ό-0.036%

Extented Hours

VOLUME

1,234,493

DAY RANGE

27.66 - 28.21

52 WEEK

21.75 - 33.71

Join Discuss about ALKS with like-minded investors

profile
@dros #droscrew
recently

$IBM Mar31 132 C $BTG Jan 7.5 C $CLF Jun 21 C $AI Apr 30 C $MS May 90 C $ALKS Apr 28 C $INTC Jan 50 C $IEI Apr 118 C $WBD Apr06 15.5 C $AAPL Jan 175 C

42 Replies 8 πŸ‘ 12 πŸ”₯

profile
@dros #droscrew
recently

$IBM Mar31 132 C $BTG Jan 7.5 C $CLF Jun 21 C $AI Apr 30 C $MS May 90 C $ALKS Apr 28 C $INTC Jan 50 C $IEI Apr 118 C $WBD Apr06 15.5 C $AAPL Jan 175 C

132 Replies 11 πŸ‘ 12 πŸ”₯

profile
@dros #droscrew
recently

RECAP 11/16 Unusual Puts: $T Nov25 18 P $XLI Mar 95 P $AAPL May 130 P $TTCF Apr 2.5 P $KSS Dec 25 P $URNM Jan 40 P $THC Dec30 32 P $URA Dec 20 P $BBWI Jan 30 P $MPW Feb 11 P $ALKS Jan 40 P $DLO Dec 5 P

136 Replies 15 πŸ‘ 9 πŸ”₯

profile
@dros #droscrew
recently

$T Nov25 18 P $XLI Mar 95 P $AAPL May 130 P $TTCF Apr 2.5 P $KSS Dec 25 P $URNM Jan 40 P $THC Dec30 32 P $URA Dec 20 P $BBWI Jan 30 P $MPW Feb 11 P $ALKS Jan 40 P $DLO Dec 5 P

47 Replies 15 πŸ‘ 8 πŸ”₯

profile
@dros #droscrew
recently

$AAPL Feb 150 C $AMZN Dec 105 C $ALLY Jan 30 C $LVS Nov 43/45 C Spd $F Jan 15 C $ARKK Dec02 41 C $BHC Dec 8 C $ALKS Jan-24 35 C $UMC Dec 7.5 C $CVNA Nov11 10 C

55 Replies 12 πŸ‘ 7 πŸ”₯

profile
@dros #droscrew
recently

RECAP 11/10 Unusual Calls: $AAPL Feb 150 C $AMZN Dec 105 C $ALLY Jan 30 C $LVS Nov 43/45 C Spd $F Jan 15 C $ARKK Dec02 41 C $BHC Dec 8 C $ALKS Jan-24 35 C $UMC Dec 7.5 C $CVNA Nov11 10 C

70 Replies 11 πŸ‘ 6 πŸ”₯

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Healthcare Alkermes ($ALKS) announced that it received notices of partial termination in respect of two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson Acadia Pharmaceuticals Inc ($ACAD) 3Q EPS ($0.09) vs est. ($0.26) on sales $131.6Mm vs est. $127.8Mm, says narrows FY Nuplazid sales guide to $480-500Mm Castle Biosciences ($CSTL) 3Q EPS ($0.47) vs est. ($0.41) on revs $23.5Mm vs est. $23Mm; says on track to achieve FY total revs guide of $89-93Mm vs est. $91.9Mm Clover Health ($CLOV) Q3 revs $427.2M vs est. $413.1M, adj EBITDA ($102.3M) vs est. ($99.5M); sees FY revs $1.42B-$1.47B vs est. $1.44B Curaleaf holdings ($CURLF) Q3 revenue $317M vs est. $328.3M, adj EBITDA $71M vs est. $92.1M; remains on track to generate revenue within lower end of $1.2B-$1.3B annual guidance range; said the acquisition of Tryke Companies reported earlier today bolsters its position in NV, AZ, UT and will be immediately accretive to margins and cash flow Fluidigm Corp ($FLDM) 3Q EPS ($0.18) vs est. ($0.22) on revs $28.5Mm vs est. $30Mm; says undertaking review of various options including with regard to strategic alternatives Invitae Corporation ($NVTA) Q3 adj EPS ($0.81) vs est. ($0.71) on revenue $114.4M vs est. $126.5M driven by billable volume 296k (+89% YoY); now sees FY revenue $450M-$475M, from $475M-$500M and below est. $484.5M Mirati Therapeutics, Inc. ($MRTX) 3Q EPS ($1.55) vs est. ($2.89) on revs $71.8Mm Nevro Corp. ($NVRO) Q3 EPS loss ($1.44) vs. est. loss (-$0.87); Q3 rev $93.2M vs. est. $91.59M; sees Q4 revs $94M-$98M Oak Street Health, Inc. ($OSH) Q3 EPS loss (-$0.49) vs. est. loss (-$0.42); Q3 revs $388.7M vs. est. $356.7M; The Company cared for approximately 100,500 risk-based patients, representing 76% of its total patients; adjusted EBITDA was $(64.3M), compared to $(22.8M) YoY SI-BONE ($SIBN) Q3 EPS ($0.48) vs est. ($0.42) on revenue $22.3M vs est. $22.5M, lowered FY21 revenue view to $89M-$90M from $92M-$94M (vs est. $92.7M) as uncertainty surrounding Covid-19’s impact on elective procedures and healthcare infrastructure remains Shockwave Medical ($SWAV) Q3 EPS $0.05 vs. est. loss (-$0.06); Q3 revs $65.2M vs. est. $61.2M; sees FY21 revenue $227M-$228M vs. est. $223.43M, which represents 235% to 236% growth YoY SmileDirectClub, Inc. ($SDC) shares fall -23%; 3Q EPS ($0.23) vs est. ($0.13) on revs $138Mm vs est. $$181Mm; guides FY revs $630-650Mm vs est. $757Mm Tactile Systems ($TCMD) shares fell -12%; 3Q EPS ($0.17) vs est. $0.12 on revs $52.5Mm vs est. $57.4Mm; sees FY revs +9-10% or $203.5M-$206M from $216.3M-$224.5M, below est. +18.7% Merck ($MRK) said the U.S. government will buy 1.4 million additional courses of their COVID-19 pill, molnupiravir, for about $1 bln and that the U.S. has now committed to purchase a total of about 3.1 million courses of molnupiravir for about $2.2 billion Haemonetics ($HAE) Q2 adj EPS $0.60 vs. est. $0.61; Q2 revs $239.9M vs. est. $241.4M; lowers FY22 adj EPS view to $2.40-$2.65 from $2.60-$3.00 and narrows its FY22 revenue view to up 13%-17% from up 13%-18% Technology, Media & Telecom Bandwidth Inc. ($BAND) Q3 adj EPS $0.25 vs. est. $0.08; Q3 revs $130.6M vs. est. $125.3M; guides Q4 EPS loss (15c-11c) vs. est. loss (-$0.01); sees Q4 revs $115.7M-$120.7M vs. est. $125.5M 3D Systems ($DDD) 3Q adj EPS $0.08 vs est. $0.05 on revs $156.1Mm vs est. $144.8Mm; guides FY adj gr mgn 41-43% vs est. 42.7% Five9 Inc. ($FIVN) 3Q adj EPS $0.28 vs est. $0.23 on revs $154.3Mm vs est. $146.8Mm; guides 4Q revs $164.5-165.5mm vs est. $157.8Mm, sees 4Q adj EPS $0.36-0.37 vs est. $0.34; sees FY revs $$600.5-601.5Mm vs est. $585.2Mm and adj EPS $1.09-1.10 vs est. $1.02 Instructure Holdings, Inc. ($INST) 3Q EPS ($0.10) vs est. $0.14 on revs $107.2Mm vs est. $101.1Mm; sees 4Q revs $106.9-107.9Mm vs est. $104.1Mm; guides FY revs $401.7-402.7Mm vs est. $397.4Mm, sees FY adj EBITDA $143.6-144.6Mm vs est. $130Mm Luminar Technologies, Inc. ($LAZR) shares rise 50%; said at the NVIDIA GTC conference that its lidar solution has been selected to be part of the sensor suite in the NVIDIA DRIVE Hyperion autonomous vehicle reference platform. This AI vehicle computing platform accelerates development of autonomous consumer vehicles with planned production starting in 2024. New Relic ($NEWR) Q2 adj EPS loss (10c) vs. est. loss (13c); Q2 revs $196M vss. Est. $182.21M; cuts FY22 adj EPS loss view to (60c)-(54c) from (52c)-(49c) while boosts FY22 revenue view to $778M-$782M from $730M-$735M (est. $736.8M) National CineMedia ($NCMI) Q3 EPS loss (19c) vs. est. loss (13c); Q3 revs $31.7M vs. est. $41.24M; Q3 adjusted OIBDA improved to negative $8.2 million for the third quarter of 2021 from negative $11.2 million for the third quarter of 2020 Roblox ($RBLX) shares rise 29%; Q3 EPS (13c) vs est. (14c) on bookings $637.8M vs est. $636.5M, revenue $509.5M, avg DAUs 47.3M vs est. 46.6M, hours engaged 11.2B (+28% YoY), avg booking per DAU $13.49 Sanmina ($SANM) Q4 adj EPS $0.95 vs. est. $0.99; Q4 revs $1.64B vs. est. $1.7B; sees Q1 adj EPS 90c-$1.00 vs. est. $1.01; sees Q1 revs $1.6B-$1.7B below consensus $1.76B Square Space ($SQSP) Q3 EPS 4c vs est. 14c on revenue $201M vs est. $205.2M; sees Q4 revenue $203M-$206M vs est. $205.2M, raised annual revenue forecast to $780M-$783M from $772M-$780M (est. $778.4M) and unlevered FCF to $117M-$122M from $102M-$116M TripAdvisor ($TRIP) 3Q adj EPS $0.16 vs est. $0.24 on revs $303Mm vs est. $304.4Mm; avg monthly unique users on branded websites rose to about 76% of 2019 comparable period; says CEO will step down during 2022 Vuzix Corporation ($VUZI) Q3 EPS loss (-$0.13), in-line with ests; Q3 revs $3.02M vs. est. $3.79M; General and Administrative expense for the three months ended September 30, 2021 was $3.1 million versus $1.6 million for the comparable 2020 period Xperi Holding Corporation ($XPER) 3Q adj EPS $0.53 vs est. $0.34 on res $219.4Mm vs est. $215.4Mm; guides FY revs $870-890Mm vs est. $882.2Mm Zynga ($ZNGA) 4Q EPS ($0.04) vs est. $0.07 on revs $704.7Mm vs est. $666Mm, qtrly bookings $668Mm +6%, average mobile DAUs 38Mm +21%, qtrly avg mobile MAUs 183Mm +120%; sees FY revs $2.78B vs est. $2.81B, sees FY bookings $2.814B

82 Replies 13 πŸ‘ 15 πŸ”₯

profile
@dros #droscrew
recently

Upgrades 9/2: $OKTA . Downgrades 9/2: $ALKS $ASMB $BUD $TCBI $UL $UN

56 Replies 12 πŸ‘ 14 πŸ”₯

profile
@Pyrognosis #droscrew
recently

BUY +4,039 $ALKS 100 17 SEP 21 29 CALL @.95 LMT

119 Replies 14 πŸ‘ 10 πŸ”₯

profile
@Pyrognosis #droscrew
recently

BUY +4,039 ALKS 100 17 SEP 21 29 CALL @.95 LMT

135 Replies 13 πŸ‘ 13 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$ALKS, $MYL, $BMY all are scheduled to have FDA news today, no specific time

63 Replies 10 πŸ‘ 8 πŸ”₯

Key Metrics

Market Cap

4.64 B

Beta

0

Avg. Volume

1.45 M

Shares Outstanding

166.56 M

Yield

0%

Public Float

0

Next Earnings Date

2023-11-01

Next Dividend Date

Company Information

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

CEO: Richard F. Pops

Website:

HQ: ,

Related News